Back

Povidone-iodine ear wash and oral cotrimoxazole for chronic suppurative otitis media in Australian Aboriginal children: a randomised controlled 2x2 factorial design trial

Beissbarth, J.; Wigger, C.; Oguoma, V. M.; Leach, A. J.; Lennox, R.; Nelson, S.; Patel, H.; Chatfield, M. D.; Currie, K.; Coates, H.; Edwards, K.; Smith-Vaughan, H. C.; Hare, K. M.; Torzillo, P. J.; Tong, S. Y. C.; Morris, P. S.

2026-07-21 infectious diseases
10.64898/2026.07.20.26358454 medRxiv
Show abstract

Objectives: To compare the effectiveness of povidone-iodine ear wash compared to no ear wash and oral cotrimoxazole compared to placebo given in addition to standard topical antibiotic treatment (ciprofloxacin drops) for chronic suppurative otitis media (CSOM) in Australian Aboriginal children. Methods: A randomised, parallel, 2 x 2 factorial design, assessor-blinded clinical trial in the remote Northern Territory of Australia. Aboriginal children with confirmed CSOM were eligible to be randomised into four treatment groups, allowing two primary treatment comparisons in a 2-in-1 trial approach. Participants received standard treatment (twice daily cleaning and topical ciprofloxacin drops) plus: i) either 16 weeks of pre-treatment povidone-iodine ear wash or no povidone-iodine ear wash; and ii) either 16 weeks of oral cotrimoxazole or placebo. Central randomisation with allocation concealment and triple-blinding of the oral antibiotic treatment arms was used. The relative risk (RR) and risk difference (RD) were estimated after adjustment for age, community, and the other intervention. The primary outcome was the proportion of children with any otorrhoea (clinical failure) after 16 weeks of treatment. Secondary outcomes included size of tympanic membrane (TM) perforation and amount of discharge, time to cessation of discharge, proportion of children with respiratory and other pathogens in ear discharge (at baseline and 16 weeks) and hearing levels (at 12 months). Findings: 280 children with CSOM were randomised and 270 had their primary outcome assessed. Clinical failure (presence of any ear discharge) after 16 weeks of treatment was 66/134 (49%) in the povidone-iodine group versus 69/136 (51%) in the no povidone-iodine group (RD= -1% (-12,11), p= 0.93) and 56/134 (42%) in the cotrimoxazole group versus 79/136 (58%) in the placebo group (RD=-16% (-28,-4), p=0.007). The amount of discharge, TM perforation size, the level of hearing impairment, and serious adverse events were not significantly different in both treatment comparisons. Anaerobic growth (24%), Pseudomonas aeruginosa (21%) and Haemophilus influenzae (17%) were the most common pathogens found in the ear discharge before treatment. Fungi or yeast (24%), Staphylococcus aureus (15%), and anaerobic growth (10%) were the common pathogens after 16 weeks of treatment, with no significant differences between groups. At 12 months post-randomisation, 55-60% of children had at least one discharging ear and there was no difference between treatment groups. Interpretation: Povidone-iodine ear washes did not contribute to better ear outcomes in this study. Cotrimoxazole for 16 weeks resulted in more children with clinical improvement to dry ears. Oral cotrimoxazole may play a role in reducing the burden of CSOM in populations with high rates of persistent disease.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

1
PLOS ONE
5266 papers in training set
Top 9%
19.0%
2
Wellcome Open Research
67 papers in training set
Top 0.1%
5.0%
3
Journal of Medical Microbiology
25 papers in training set
Top 0.1%
4.4%
4
PLOS Global Public Health
344 papers in training set
Top 4%
3.6%
5
Scientific Reports
3612 papers in training set
Top 31%
3.3%
6
BMJ Open
601 papers in training set
Top 8%
2.5%
7
The Lancet
16 papers in training set
Top 0.1%
2.5%
8
The Journal of Infectious Diseases
202 papers in training set
Top 2%
2.2%
9
The Lancet Microbe
44 papers in training set
Top 0.3%
2.2%
10
International Journal of Infectious Diseases
129 papers in training set
Top 1%
2.0%
11
Clinical Infectious Diseases
235 papers in training set
Top 1%
1.8%
12
Journal of Infection
78 papers in training set
Top 0.7%
1.5%
50% of probability mass above
13
Pediatric Infectious Disease Journal
17 papers in training set
Top 0.2%
1.5%
14
Journal of Clinical Medicine
97 papers in training set
Top 3%
1.5%
15
Clinical Microbiology and Infection
62 papers in training set
Top 0.5%
1.2%
16
Antimicrobial Resistance & Infection Control
11 papers in training set
Top 0.2%
1.1%
17
The Lancet Infectious Diseases
73 papers in training set
Top 1%
1.1%
18
Journal of Hospital Infection
29 papers in training set
Top 0.3%
1.1%
19
The Journal of Pediatrics
16 papers in training set
Top 0.3%
1.1%
20
Trials
29 papers in training set
Top 0.8%
1.0%
21
PLOS Medicine
110 papers in training set
Top 3%
1.0%
22
European Respiratory Journal
59 papers in training set
Top 1%
0.9%
23
Thorax
35 papers in training set
Top 0.6%
0.9%
24
Frontiers in Pediatrics
32 papers in training set
Top 0.9%
0.9%
25
Pathogens
56 papers in training set
Top 1%
0.9%
26
New England Journal of Medicine
52 papers in training set
Top 0.5%
0.9%
27
Nature Communications
5641 papers in training set
Top 55%
0.9%
28
Hearing Research
54 papers in training set
Top 0.4%
0.9%
29
Frontiers in Public Health
148 papers in training set
Top 6%
0.9%
30
Pilot and Feasibility Studies
14 papers in training set
Top 0.6%
0.9%